At the meeting of 12 December 2018 the RMA:
Determined Statements of Principles (SOPs) for:
|iliotibial band syndrome||3/2019||4/2019|
|human immunodeficiency virus infection||5/2019||6/2019|
|internal derangement of the knee||7/2019||8/2019|
These SOPs revoke the SOPs previously determined for these conditions.
Determined Amendment Statements of Principles (SOPs) for:
The above SOPs take effect from 28 January 2019. The SOPs concerning localised sclerosis take effect from 23 July 2018.
Decided to Undertake Consultation regarding:
|Condition||Reasons for Decision||Date for Final Decision|
|gout||Intention to remove one or more factors||April 2019|
|dislocation of a joint and subluxation of a joint||Intention to remove one or more factors||April 2019|
|joint instability||Intention to remove one or more factors||April 2019|
The above determinations conclude the previously advertised investigations into:
- chondromalacia patella
- iliotibial band syndrome
- human immunodeficiency virus infection
- internal derangement of the knee
- Dupuytren disease
- sarcoidosis (focussed review - cancer and cancer treatment)
The investigation concerning 'Dupuytren's disease' has resulted in the determination of Statements of Principles concerning Dupuytren disease.
The investigation concerning 'human immunodeficiency virus' has resulted in the determination of Statements of Principles concerning human immunodeficiency virus infection.
The Amendment Statements of Principles concerning localised sclerosis correct a typographical error identified in the Statements of Principles concerning localised sclerosis (Nos. 61 & 62 of 2018). These Amendment Statements of Principles will have the same commencement date as the Statements of Principles concerning localised sclerosis (Nos. 61 & 62 of 2018).
Decided to advertise the following investigations:
- aortic aneurysm (focussed review - passive smoking)
- hypertension (focussed - exposure to phenoxyherbicides/dioxin (Agent Orange))
- malignant melanoma of the skin (focussed - firefighting)
- monoclonal gammopathy of undetermined significance (MGUS)
The above investigation notices appear in the Government Notices Gazette of 8 January 2019.